Last Updated : August 7, 2025
Details
FilesGeneric Name:
cabozantinib
Project Status:
Active
Therapeutic Area:
Neuroendocrine tumours
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
PX0378-000
Call for patient/clinician input closed:
Biosimilar:
No
Submission Type:
Non-sponsored Submission
Submission Complexity:
Standard Review
Fee Schedule:
Pending
Indications:
For the treatment of locally advanced or metastatic extra-pancreatic (ep-NET) or pancreatic neuroendocrine tumours (nPNET).
| Review initiated | 06-Feb-25 |
|---|---|
| Expert committee meeting (initial) | 17-Jul-25 |
Files
Last Updated : August 7, 2025